ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-mutated citrullinated vimentin"

  • Abstract Number: 452 • 2019 ACR/ARP Annual Meeting

    Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients

    Georg Schett1, David Simon 2, Axel Hueber 2, Holger Bang 3, Jürgen Rech 4, Gerhard Kroenke 5 and Arnd Kleyer 6, 1Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Orgentec Diagnostika, 55129 Mainz, Germany, Mainz, 4Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Austria, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Autoimmunity, characterized by the presence of anti-modified protein antibodies (AMPA), recognizing citrullinated, carbamylated or acetylated proteins, as well as rheumatoid factor (RF) precedes the…
  • Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting

    Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year

    Yannick Degboé1, Arnaud Constantin2, Delphine Nigon3, Gabriel Tobon4, Martin Cornillet5, Thierry Schaeverbeke6, Gilles Chiocchia7, Pascale Nicaise-Roland8, Leonor Nogueira9, Guy Serre5,10,11, Alain G. Cantagrel12 and Adeline Ruyssen Witrand13,14, 1Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, 2Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, 3CHU Purpan, Toulouse, France, 4Rheumatology Department, la Cavale Blanche Hospital, Brest, France, 5Service de Biologie Cellulaire, C.H.U. Purpan, Toulouse, France, 6CHU Bordeaux, Bordeaux, France, 7Immunology-Rheumatology, INSERM U1173, paris, France, 8Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, 9Immunology, UMR CNRS 5165, INSERM 1056, Toulouse, France, 10Cell Biology, Purpan University Hospital, Toulouse, France, 11Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM,Toulouse, France, Toulouse, France, 12Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 13Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 14UMR 1027, Inserm, Toulouse, France

    Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…
  • Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting

    Antibodies to Citrullinated Peptides in Tuberculosis

    Isabella Lima1, Rodrigo Oliveira2, Ajax Atta2, Samyra Marchi3, Lúcio Barbosa3, Eliana Reis3, Mitermayer G. Reis3 and Mittermayer Santiago4, 1Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, 2Universidade Federal da Bahia, Salvador, Brazil, 3Fundação Oswaldo Cruz, Salvador, Brazil, 4Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology